医学
淀粉样变性
淀粉样变性
炎症性肠病
英夫利昔单抗
胃肠病学
血清淀粉样蛋白A
免疫抑制
乌斯特基努马
血清淀粉样蛋白A
炎症
内科学
并发症
溃疡性结肠炎
淀粉样蛋白(真菌学)
免疫学
疾病
病理
家族性地中海热
作者
Marouf Alhalabi,Kamal Alaa Eddin,Ahmad Abbas
标识
DOI:10.1097/meg.0000000000002649
摘要
AA amyloidosis is a rare and significant complication of long-term inflammation that can be caused by a variety of disorders, including inflammatory bowel disease, and is linked to an increased risk of morbidity and mortality. To date, there has been no effective direct treatment, and treatment aims at treating the underlying condition with potent immunosuppression to limit inflammatory activity and, as a result, switch off amyloidogenesis. Theoretically, biological treatment can control AA amyloidosis by inducing and maintaining inflammatory bowel disease remission and inhibiting the synthesis of Serum Amyloid A, which is an acute phase reactant and precursor protein of AA amyloidosis that accumulates in the organs. We report the first case of ustekinumab’s therapeutic effect after infliximab’s loss of response in AA amyloidosis associated with Crohn’s disease. We also conducted a literature review of the therapeutic effect of biological treatment on AA amyloidosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI